Patient-reported Outcomes and Healthcare Provider Perspectives on Subcutaneous Isatuximab Delivery via On-body Injector Versus Manual Injection: Results From the Phase 2 IZALCO Study in Relapsed/Refractory Multiple Myeloma

Clinical Lymphoma, Myeloma & Leukemia · Elsevier

Аннотация

Publication date: November 2026 Source: Clinical Lymphoma Myeloma and Leukemia, Volume 26, Issue 11 Author(s): Gurdeep Parmar, Marcelo Capra, Vania Hungria, Fernanda Salles Seguro, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, Ivan Špička, Jiří Minařík, Herlander Marques, Ludĕk Pour, Jana Mihályová, Junichiro Yuda, Kazutaka Sunami, Graça Esteves, Cynthia Chmielewski, Christine Soufflet, Disa Yu, Erin Comerford, Florence Suzan, Paul Cordero

Читать у издателя →

Похожие статьи